Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving

摘要

AimTo identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to inhaled corticosteroids might be a cost-effective option for individuals with asthma.